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Abstract 
Aims: We aimed to test whether specific insight dimensions are associated with 
suicidality in patients with psychotic disorders. Methods: 143 patients with 
schizophrenia spectrum disorders were recruited. Suicidality was assessed by item 8 of 
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the Calgary Depression Scale for Schizophrenia (CDSS). Insight was measured by the 
Scale of Unawareness of Mental Disorder (SUMD) and the Markova and Berrios 
Insight Scale. Bivariate analyses and multivariable logistic regression models were 
conducted. Results: Those subjects aware of having a mental illness and its social 
consequences had higher scores on suicidality than those with poor insight. Awareness 
of the need for treatment was not linked with suicidality. The Markova and Berrios 
Insight scale total score and two specific domains (awareness of  “disturbed thinking 
and loss of control over the situation” and “having a vague feeling that something is 
wrong”) were related to suicidality. However, no insight dimensions survived the 
multivariable regression model, which found depression and previous suicidal 
behaviour to predict suicidality. Conclusions: Suicidality in psychosis was linked with 
some insight dimensions: awareness of mental illness and awareness of social 
consequences, but not compliance. Depression and previous suicidal behaviour 
mediated the associations with insight; thus, predicting suicidality.  
Key words:  
Schizophrenia, schizophrenia spectrum disorders, insight dimensions, depression, 
suicidal ideation, suicide attempt 
 
 
 
 
 
 
 
 
 
1. Introduction 
 
 As many as one in two patients with schizophrenia have had lifetime suicidal 
thoughts or attempted suicide (Bolton et al., 2007). Approximately 2-5% of these 
patients die from suicide (Palmer et al., 2005; Dutta et al., 2010). 
 Suicide in schizophrenia has been linked with some general suicide risk factors 
such as depression (Hawton et al., 2005; Pluck et al., 2012; Challis et al., 2013), 
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previous suicide attempts (Melle et al., 2012; Pluck et al., 2012; Barret et al, 2015), 
impulsive personality traits (Pluck et al., 2013), drug and alcohol misuse (Hawton et al., 
2005; Pluck et al., 2012), and feelings of hopelessness (Melle et al., 2012). In addition, 
poor adherence to treatment (Hawton et al., 2005; Mork et al., 2012), greater number of 
previous hospital admissions (Popovic et al., 2014), less severe negative symptoms 
(Fenton, 2000), early phases of the illness (Fenton et al., 2000; Palmer et al., 2005; 
Dutta et al., 2010 Melle et al., 2012; ), younger age at psychosis onset (Mork et al., 
2012), being male (Hawton et al., 2005), longer “duration of untreated psychosis” 
(DUP) (Challis et al., 2013; Lopez-Moriñigo et al., 2014), higher premorbid intelligence 
quotient (IQ) (Pluck et al., 2012) and family history of self-harm (Pluck et al., 2012) 
have been specifically associated with an increased suicide risk in psychosis. In 
addition, some medication side effects such as akathisia have been related to suicide 
attempts (Scholten et al., 2005). 
 Mixed results have been reported regarding the relationship between insight and 
suicide, including both positive (i.e. insight as a risk factor for suicide) and negative 
studies (i.e. insight behaving as a protective factor for suicide) (Lopez-Morinigo et al., 
2012). Moreover, findings from a recent 1-year follow-up first-episode psychosis (FEP) 
study suggest that this relationship may change over the course of the illness. Thus, 
insight at baseline was found to be associated with increased risk of suicidality at 1-
year, whilst the increase in insight over the 1-year follow-up reduced the risk at that 
point (Barret et al., 2015). 
 Hence, while clinical insight has been classically linked to better long-term 
outcomes in psychosis via improved compliance (Bourgeois et al., 2004; Lincoln et al., 
2007; Higashi et al., 2013), which has also been found to reduce suicide risk in 
schizophrenia (Hawton et al., 2005) and FEP (Barrett et al., 2015), concerns have been 
raised regarding a potential association of insight with suicidality via depression and 
hopelessness, i.e. the so-called demoralization syndrome (Drake and Cotton, 1986; 
Crumlish et al., 2005; Restifo et al., 2009). One possible explanation for these mixed 
findings may be related to the unidimensional approach to insight taken by some of 
these studies  (Lopez-Morinigo et al., 2012) since over the last two decades insight has 
been demonstrated to be a multidimensional phenomenon (David et al., 1990; Amador 
et al., 1991; Amador and David, 2004), including:  1) awareness of having a mental 
disorder, 2) awareness of the effects of medication, 3) awareness of the social 
consequences of disorder, and 4) the ability to relabel psychotic experiences as 
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abnormal. In keeping with this, two clinical rater-based scales to assess insight 
multidimensionally have been validated to date: the Scale of Unawareness of Mental 
Disorder (SUMD) (Amador et al., 1991) and the Scale for Assessment of Insight (SAI) 
(David, 1990) and its expanded version (SAI-E) (Kemp and David, 1997).  Thus, while 
some insight dimensions such as awareness of psychotic symptoms may behave as risk 
factors for suicide, awareness of the benefits from treatment appears to reduce suicide 
risk in schizophrenia (e.g. Amador et al., 1996).  
 In keeping with this, we found four recent studies which investigated the 
relationship between suicidality and insight from a multidimensional perspective. 
Interestingly, while the three cross-sectional studies (Flanagan et al., 2012, Sharaf et al., 
2012; Lopez-Moriñigo et al., 2014) revealed positive associations of insight with 
suicidality, a 3-year follow-up FEP study failed to replicate such associations (Ayesa-
Arriola et al., 2015).  
 In addition, there are further aspects of insight concerning the subjective and 
cognitive domains of the self, which can only be captured by self-rated scales such as 
the Markova and Berrios Insight Scale (Markova et al., 1992; Markova et al., 1995), 
which will be referred to as subjective insight hereafter. To the best of our knowledge, 
the relationship between these aspects of insight and suicide risk in psychosis has not 
been studied to date. 
We aimed to investigate the association of multiple insight dimensions with 
suicidality, whilst adjusting the analyses for a set of sociodemographic and clinical 
variables. Specifically, we hypothesised that: (i) regarding clinical insight, while 
awareness of having a mental illness and awareness of the social consequences of the 
illness increase suicide risk, awareness of the need for treatment behaves as a protective 
factor; (ii) with regard to subjective insight, higher levels of “self-reported” insight is 
associated with increased suicidality.  
2. Methods 
 
2.1 Participants 
Patients were recruited over March 2009-December 2014 from a            
publicly-funded general hospital in Barcelona (Spain), which provides secondary 
mental healthcare to a population of approximately 450.000 people. Both in- and 
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outpatients were approached and invited to participate in the study. The sample was 
therefore mixed in terms of demographics, but also illness severity, with a wide range of 
scores in the psychopathological assessments, thus demonstrating the real-world nature 
of our data. Inclusion criteria were as follows: age 18-80 years and fulfilling DSM-IV 
criteria for schizophrenia spectrum disorders, including schizophrenia and 
schizophreniform disorder (“schizophrenia spectrum disorders”), schizoaffective 
disorder, delusional disorder, brief psychosis and psychosis NOS (American Psychiatric 
Association, 1994). Diagnoses were made by the clinical team, which was led by a 
consultant psychiatrist. Clinical consensus meetings took place on a monthly basis. 
Patients with moderate to severe learning disabilities (IQ<65), a neurological illness 
and/or a history of severe head trauma were excluded. All participants provided written 
informed consent. The study was approved by the medical research ethics committee of 
the hospital (CEIC code 2006/510). 
 
2.2 Assessments 
Demographic variables included gender (male/female), age at the time of the 
assessment, education level (which was dichotomised: up to primary school vs. further 
levels), employment status (unemployed/employed), marital status (unmarried/married) 
and living status (alone/not alone).  
2.2.1 Insight 
Insight was assessed using two different scales. First, the Spanish version of the 
Scale of Unawareness of Mental Disorder (SUMD) (Amador et al., 1993; Ruiz et al., 
2008) was administered to evaluate clinical insight. The SUMD assesses ‘lack of’ 
insight, i.e. the higher the score (ranging from 0 to 5), the poorer the insight, which 
provides scores on three insight dimensions: mental illness (IMI), need for treatment 
(INT) and social consequences (ISC).  The sample was dichotomized into “poor 
insight” (all scores over 1) and “good insight” (scores of 1) for each insight dimension.   
In order to evaluate subjective insight considering patients’ views, the Markova 
and Berrios Insight Scale (MBIS) (Markova et al., 1992; Markova et al., 1995) Spanish 
version (Nieto et al., 2012) was also administered. This scale consists of 30 statements 
which are labelled by patients as true or false. Higher scores correlate with greater 
insight.  Both total insight (scored by summing all the items) and the following insight 
dimensions were analysed: (MF1) awareness of disturbed thinking and loss of control 
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over the situation, (MF2) acknowledgment that things outside as well as within the 
individual feel different, (MF3) having a vague feeling that something is wrong and 
(MF4) attributing perceived changes to physical problems (Markova et al., 2003). 
2.2.2 Psychopathology 
 Severity of positive and negative symptoms over the last week was assessed by 
the Spanish version of the Positive and Negative Syndrome Scale for Schizophrenia 
(PANSS) (Kay et al., 1987). The PANSS is a 30-item scale with scores ranging from 1 
to 7 (i.e. the higher the score, the more severe the symptom), which can also be summed 
to obtain overall measures of psychopathology.  Five symptomatic domains, including 
positive, negative, disorganization, excitation and depression, were considered based on 
a previous factor analysis (Lindenmayer et al, 1995).  
2.2.3 Suicidality 
Current (i.e. over the last two weeks) ‘suicidality’ was assessed by item 8 of the 
Calgary Depression Scale for Schizophrenia (CDSS) (Addington et al., 1992) Spanish 
validated version (Sarro et al., 2004), which ranges from 0 (no suicidal ideation at all 
over the last two weeks) to 3 (at least one suicide attempt or serious plan over this 
period). The presence of suicide attempts prior to the assessment (and the number of 
such suicide attempts) was taken from patient’s records. A ‘suicide attempt’ was 
defined as ‘a potentially self-injurious behaviour with a nonfatal outcome, for which 
there was evidence (either explicit or implicit) that the person intended to kill 
him/herself’ (O’Carroll et al., 1996). However, neither the remaining CDSS items nor 
the total score were included in the analyses to evaluate suicidality (main outcome 
measure) and depression (one of the independent variables) with different scales, in 
order to avoid a potential bias related to multi-collinearity.  
2.2.4 Other clinical variables 
Other potential contributing factors to suicidal behaviour were considered. The 
validated Spanish version of the Drug Attitude inventory (DAI) was administered to 
participants (Robles García et al., 2004). DAI scale is a self-report scale which assesses 
attitudes (which can be positive or negative according to the total score) towards 
maintenance antipsychotic drug therapy (Hogan et al., 1983). 
Some items of the Udvalg for Kliniske Undersøgelser side effect rating scale 
(UKU side effect scale) (Lingjaerd et al., 1987) were also taken. UKU scale measures 
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psychological, neurological and autonomic side effects with scores ranging from 0 
(absent) to 3 (very severe).  
Also, the validated Spanish version of the Screen for Cognitive Impairment in 
Psychiatry (SCIP) (Pino et al., 2006) was administered to assess general cognition. 
Results from the SCIP were dichotomized in a “moderate/severe impairment” group and 
a “mild or absent cognitive impairment” group. 
Other clinical variables, such as DSM-IV diagnosis (F2: ‘schizophrenia 
spectrum disorder’ vs. ‘other psychoses’), illness duration (years), family history of 
psychiatric illness (present/absent), alcohol and illicit drug use (present/absent) and 
pharmacological treatment (antipsychotics, clozapine and antidepressants: use vs. non-
use), were also recorded. 
 
2.3 Statistical analysis 
Statistical analyses were performed using SPSS version 22.0 (SPSS Inc, 
Chicago, Il, USA).  
First, we investigated potential bivariate associations of demographic and 
clinical variables with: (i) past suicidal history by using parametric and non-parametric 
tests depending on variable distribution (normal/non-normal), such as t-tests, Mann-
Whitney U–tests and chi-square (applying Yates correction if necessary); (ii) the degree 
of suicidality, i.e. item 8 of the CDSS, over the two weeks preceding the assessment. 
These analyses formed the basis for further multivariable linear regression models with 
CDSS item 8 as the main outcome measure so they were unadjusted. 
Second, a multiple hierarchical linear regression model (enter method) with 
suicidality (which was measured with item 8 of the CDSS) as the dependent variable 
was carried out to investigate predictors of suicidality, whilst adjusting the analyses for 
potential mediating/confounding demographic and clinical variables. No further CDSS 
scores were included in the model in order to investigate the influence of depression on 
suicidality by measuring it with a different instrument (namely, the PANSS factor). The 
change of the percentage of variance explained by each block of variables (Nagelkerke 
R
2
) and the contribution of each independent variable to the model were investigated. 
All the above analyses were two-tailed and the level of significance was set at 5%. 
 
3. Results 
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The sociodemographic and clinical characteristics of the sample (n=143) are 
summarised in Table 1. The sample was mixed (mean age at first contact: 38.4±11.9 
years) and only 14 patients (9.8%) had a duration of illness shorter than one year. 92 
individuals (64.3%) were diagnosed with schizophrenia. 38 patients (26.6%) had 
attempted suicide before the study entry (see Table 1).  
The differences in background and baseline variables in relation to current 
suicidality, which was measured with the CDSS item 8, are presented in Table 2. 
Potential bivariate correlations between continuous variables and suicidality are also 
reported in Table 3. 
The mean score for suicidality was 0.4±0.8. With regards to clinical insight, 
those subjects with good insight of mental illness and social consequences scored 
significantly higher on suicidality than those with poor insight into these dimensions as 
follows: 0.7±1.1 vs 0.4±0.7, p<0.001 and 0.6±0.9 vs 0.4±0.8, p=0.04, respectively 
(Table 3). In addition, total MBIS score (r=0.35, p<0.001) and MF1 (awareness of 
“disturbed thinking and loss of control over the situation”) (r=0.36, p<0.001) and MF3 
(“having a vague feeling that something is wrong”) (r=0.20, p=0.02) were significantly 
associated with suicidality.  
Also, the suicidality score was higher in those who were unemployed (0.5±0.8 
vs 0.2±0.4, p=0.004) and single (0.5±0.8 vs 0.3±0.7, p=0.045). Depression measures 
such as the PANSS affective factor significantly correlated with suicidality: r=0.45, 
p<0.001. Also, the PANSS negative factor correlated significantly with suicidality 
(r=0.45, p< 0.001). Finally, those individuals on antidepressant treatment showed 
greater suicidality than those who were free of this medication (0.9±1.2 vs 0.3±0.7, 
p<0.001).  
A multivariable regression analysis investigated suicidality (CDSS item 8) as the 
dependent variable. Unemployment, marital status, previous suicide attempts, PANSS 
Affective and Negative factors, awareness of mental illness (SUMD1), awareness of the 
social consequences of the illness (SUMD3) and the total MBIS score were added to the 
model. However, only depression (as measured by the PANSS factor) (p<0.001) and 
previous suicidal behaviour (p=0.02) remained as significant factors. This model 
explained 34.5% of the variance on suicidality (Table 4).  
 
4. Discussion 
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 4.1 Principal findings 
We aimed to investigate the role of insight dimensions in suicidality in patients 
with schizophrenia and related disorders, whilst considering potential 
mediating/confounding factors, including a wide range of demographic and clinical 
variables. In line with our first hypothesis concerning clinical insight, we found that 
those patients with good insight into having a mental illness and insight into the social 
consequences had greater levels of suicidality at the time of the assessment, whereas 
awareness of the need for treatment did not show this relationship. However, no insight 
score survived the multivariable regression model, which found depression and previous 
suicidal history to predict suicidality, thus mediating the above relationships between 
insight dimensions and suicidality.  
In keeping with our second hypothesis, two insight domains from the patient’s 
perspective, namely “awareness of disturbed thinking and loss of control over the 
situation” and “having a vague feeling that something is wrong”, were linked with 
suicidality. Again, contrary to our expectations, the relationships between subjective 
insight dimensions and suicidality did not remain significant in the final multivariable 
regression model, hence suggesting that depression and previous suicidal behaviour 
may mediate the above associations of subjective insight with suicidality. 
 
4. 2 Clinical Insight dimensions and suicidality 
Regarding clinical insight and suicidality, we found an association between two 
dimensions of clinical insight (Insight of mental illness and Insight of social 
consequences) and suicidality, which is consistent with previous literature (Lopez-
Morinigo et al., 2012).  In keeping with this, the first study investigating this complex 
association (Amador et al., 1996) reported symptoms relabeling to be associated with 
previous suicidal behaviour, which is consistent with a more recent FEP study which 
linked suicidality with recognition of mental illness and the ability to relabel psychotic 
symptoms as pathological (Flanagan et al., 2012). Interestingly, in our previous 
systematic review (Lopez-Morinigo et al., 2012) we concluded that  insight was no 
longer significantly associated with greater risk of suicide after conducting 
multivariable regression analyses in at least six selected studies (Kim et al., 2003; 
Bourgeois et al., 2004; Evren et al., 2004; Bakst et al., 2010; Robinson et al., 2010; Kao 
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& Liu, 2011). Also, the multivariable regression analyses tended to find depression as 
the main contributor to suicide risk (e.g. Restifo et al., 2009; Baskt et al., 2010; Barrett 
et al., 2011). This is in full agreement with our present study which revealed that while 
Insight of mental illness and Insight of social consequences were associated with 
suicidality in the bivariate analyses, the multivariate models reported depression and 
previous suicidal history to determine suicidality, thus mediating the relationship 
between insight dimensions and suicidality. Indeed, insight in psychosis has been 
consistently linked with depression (Mintz et al., 2003, Belvederi Murri et al., 2015) 
and previous suicide attempts (Lopez-Morinigo et al., 2014). 
 Also, contrary to our hypothesis based on previous literature (e.g. Hawton et 
al., 2005), we failed to replicate the protective effect of Insight of need of treatment on 
suicidality, although these results were consistent with recent FEP studies (Ayesa-
Arriola et al., 2015; Barrett et al., 2015).  Finally, we showed different associations 
between suicidality and each insight dimension, which provides further support for the 
multidimensional model of insight (Amador and David, 2004) 
 
           4.3. Subjective insight and suicidality 
 In our study, we strengthened the measurement of insight by administering the 
MBIS which considers patient’s self-report of insight. It has been postulated that insight 
might be a way of self-knowledge, i.e. how one feels and not just what is happening to 
one’s self. Thus, when assessing insight this scale considers not only both aspects of the 
subjective experience (of psychosis), but also aspects of attribution and delusional 
interpretation of reality. 
 To our knowledge, no previous studies have investigated the relationships of 
suicidality and insight dimensions as assessed by the MBIS, which provides information 
on ‘subjective insight’. However, in keeping with our results, a previous study reported 
a link between ‘self-disorders’, i.e. subtle disturbances of the person’s spontaneous 
experiences of him/herself as a vital subject naturally immersed in the world (which is 
therefore a subjective insight domain), suicidality and depression in patients with 
schizophrenia (Haug et al., 2012). 
 
4.4 Predictors of suicidality 
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Previous suicidal behaviour has been consistently found to be the strongest risk 
factor for suicide in schizophrenia (Hawton et al., 2005; Melle et al., 2012) and FEP 
(e.g. Barret et al, 2015), which  was replicated by our results. 
In keeping with previous literature concerning suicide and psychosis, in our 
sample we also replicated the association between suicidality and being single (Balhara 
et al., 2012) and unemployed (Sharaf et al., 2012). Similarly, previous studies had 
reported social isolation to be related to suicide risk (Pješčić et al., 2014). 
 In addition, we found that taking antidepressant treatment was related to 
suicidality. However, this finding may have been the result of putting high-risk patients 
on these medications to better manage their depression (Hawton et al., 2005; Pluck et 
al., 2012; Challis et al., 2013). Indeed, no conclusions about causality can be drawn 
from our cross-sectional study.  
Although some previous reports found cognition to be associated with increased 
suicidality (Nangle et al., 2006; Delaney et al., 2012), our results did not replicate such 
an association, which is consistent with other groups (e.g. Barrett et al., 2011). 
Of relevance, the predictors of suicidality that emerged from the multivariable 
regression model were depression and previous suicidal behaviour, which is in line with 
previous literature on suicide in schizophrenia (Hawton et al., 2005). Also, two meta-
analyses (Mintz et al, 2003; Belvederi et al., 2015) have linked depression with 
awareness of mental illness and the social consequences of the illness, although no such 
associations were found with compliance. Although our regression model only 
explained 34.5% of the variance on suicidality, thus suggesting that other variables 
seem to play a role in suicidality in psychosis, awareness of having a mental illness 
showed a borderline association with suicidality. In the light of this result, further 
studies appear to be warranted in order to clarify the extent to which insight, particularly 
recognition of mental illness, contributes to suicidality in psychosis. It should be also 
noted that insight levels change over the course of the illness (Ayesa-Arriola et al., 
2014).  As a result, prolonged longitudinal studies looking at the association of insight 
levels with suicidality over the follow-up are needed (Barret et al., 2015).  
  
 4.5 Strengths and limitations 
 We have investigated the relationship between multiple insight dimensions and 
suicidality in psychosis. We recruited a relatively large mixed sample of patients with 
schizophrenia spectrum disorder from our catchment area who presented to both in- and 
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outpatient mental health services, thus reflecting real-world nature of our patients, rather 
than a convenience sample. Our study may therefore have overcome some of the 
potential limitations related to using ‘FEP’ samples. In addition, insight was assessed 
multidimensionally by using two different validated scales and potential mediating 
variables such as psychopathological symptoms, drugs abuse, patient attitude towards 
medication (DAI scale) and the presence of side effects (UKU scale) were properly 
evaluated.  
 However, several limitations of our study should be considered when 
interpreting our results. First, according to previous literature other non-tested variables 
such as DUP (Lopez-Morinigo et al., 2014), premorbid functioning (Barret et al., 2015), 
premorbid personality traits (particularly impulsivity) (Melle et al., 2012), premorbid 
adjustment (Ayesa-Arriola et al., 2015), family history of self-harm (Drake et al., 1986; 
Balhara et., al 2012; Pluck et al., 2013) and internalized stigma (Sharaf et al., 2012; 
Belvederi et al., 2015) may contribute to suicidality in psychosis. However, in our study 
these variables could not be included because they either had not been electronically 
recorded prior to the patient’s assessment (e.g. DUP; Lopez-Morinigo et al., 2014) or 
they were not included in our initial protocol (e.g. premorbid adjustment; Ayesa-Arriola 
et al., 2015).  
 Second, the cross-sectional design of our study did not allow us to infer 
causality conclusions. Specifically, insight has been reported to evolve over time 
(Ayesa-Arriola et al., 2014). Therefore, the association of insight dimensions with 
suicidality may change over the course of the illness (Barrett et al., 2015). Third, a 
specific scale to assess suicidality may have been more sensitive in detecting subtle 
differences in suicidal ideation (Sharaf et al., 2012). Finally, further differences may not 
have been detected due to insufficient statistical power.  
    Further longitudinal studies with larger samples and more prolonged follow-up 
periods are needed in order to ascertain the multiple predictors of suicidality over time, 
including insight measures, with sufficient statistical power. In addition, given the well-
known association of previous suicidal history with both future suicidal acts (Hawton et 
al., 2005) and insight levels (e.g. Lopez-Morinigo et al., 2014), further studies with 
large samples are warranted to allow secondary analyses by subgroups of patients 
with/without suicidal history, which may shed light on the complex association between 
previous suicidal history, insight levels and future suicidality.   
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4. 6 Clinical implications and conclusions 
Interestingly, our findings do not appear to support the commonly held clinical 
view that insight is associated with an increased suicide risk in patients with psychosis. 
Specifically, we found bivariate associations of two insight dimensions (Insight of 
mental illness and Insight of social consequences) with suicidality, which links with the 
debate about the so-called ‘Insight Paradox’ (Lysaker et al., 2007).  On the one hand, 
insight is associated with better outcomes via improved compliance (McEvoy et al., 
2006; Lincoln et al., 2007). On the other hand, some, but not all, aspects of insight may 
be related to demoralization and increased suicidality (Drake and Cotton, 1986), despite 
recent literature (e.g. Ayesa-Arriola et al., 2015), including this study, not supporting 
this assertion. Moreover, it seems that those aspects of insight related to compliance and 
engagement appear to mediate the association of insight with depression, i.e. the greater 
the engagement, the weaker such an association (Belvederri Murri et al., 2015). We may 
therefore speculate that the greater the engagement, the weaker the association between 
insight and suicidality, although to the best of our knowledge this has not been 
investigated to date.   
However, we replicated (see Lopez-Morinigo et al., 2012) that the relationships 
between insight dimensions and suicidality are mediated by other variables, namely 
depression and previous suicidal behaviour. Hence, more theoretical research is needed 
to determine the direction of causality between insight and depression (Belvederri Murri 
et al., 2015). In particular, it seems that internalised stigma (Lysaker et al., 2007; Sharaf 
et al., 2012), engagement, illness severity and socioeconomic status mediate the 
relationships between insight and depression (Belvederri Murri et al., 2015).    
The replication of our findings concerning the lack of a direct association of 
insight dimensions with suicidality, or even its potential protective role (e.g. Barrett et 
al., 2015), may lead to the development and implementation of suicide prevention 
strategies in psychosis focused on certain insight dimensions. Truly, longitudinal studies 
are needed to demonstrate if an insight improving intervention may reduce suicide risk 
in patients with psychosis.  
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Table 1. Background and baseline characteristics of the sample  
 Total 
sample 
(n=143) 
Previous suicide attempts 
 
Previous 
suicidal 
history 
38 
(26.6%) 
Non-
suicide 
attempters 
 105 
(73.4%) 
p-
value 
23 
 
 n (%) n (%) n (%)  
Gender (females) 54 (37.8) 18 (47.4) 36 (34.3) 0.154 
Marital status (single) 114 (79.7) 32 (84.2) 82 (78) 0.422 
Family psychiatric history 73 (51.4) 10 (26.3) 28 (26.7) 0.831 
Living alone  88 (78.3) 20 (52.6) 68 (64.8) 0.143 
Level of education (Primary school) 132 (92.3) 36 (94.8) 96 (91.4) 0.512 
Job status (unemployed/working)  128 (90.8) 35 (92.1) 93 (88.6) 0.350 
Illness duration shorter than one year 14 (9.8) 3 (7.9) 11 (10.5) 0.646 
Diagnosis of schizophrenia      92 (64.3) 22 (57.9) 70 (66.7) 0.333 
Alcohol use 34 (23.8) 25 (65.8) 9 (8.6) 0.988 
Illicit drugs use 36 (25.2) 28 (73.7) 8 (7.6) 0.494 
Depot 69 (48.3) 16 (42.1) 53 (50.5) 0.376 
Clozapine 20 (14.0) 5 (13.2) 15 (14.3) 0.864 
Antidepressant 27 (20.8) 14 (36.9) 13 (12.4) 0.002 
Mood stabilizer 24 (17.3) 11 (28.9) 13 (12.4) 0.025 
Insight mental illness 35 (24.5) 13 (34.2) 22 (21) 0.103 
Insight need for treatment 61 (42.7) 15 (39.5) 46 (43.8) 0.645 
Insight social consequences 36 (25.2) 9 (23.7) 27 (25.7) 0.805 
Cognitive impairment (SCIP) 96 (75%) 27 (71.1) 69(65.7) 1.000 
 Mean ± SD    
Age at assessment (years)  38.4± 11.9 39.6 ±11.3 37.9 ± 12.1 0.998 
Lifetime hospital admissions 3.6± 2.5 4.0±1.8 3.4±2.7 0.031 
Total Markova & Berrios Insight scale 13.9± 5.5 15.9±5.2 13.1±5.4 0.008 
MF 1 ( disturbed thinking)  3.0±2.2 4.1±2.2 2.6±2.1 0.001 
MF 2 (things feel different) 3.1±1.0 3.2±0.9 3.1±1.1 0.425 
MF 3 (something is wrong) 1.5±0.9 1.6±0.8 1.4±1.0 0.124 
MF 4 (changes are due to physical 
problems) 
    1.0±0.7 0.9±0.7 1.0±0.7 0.932 
Total PANSS 85.8 ± 25.6 90.6± 23.0 84.0± 21.0 0.473 
PANSS-Positive 22.6 ± 6.7 22.8± 6.7 22.6± 6.8 0.727 
PANSS-Negative 21.0 ± 9.5 23.3± 9.7 20.2± 9.3 0.799 
PANSS-Disorganized 19.0 ± 6.8 19.6± 6.2 18.9± 7.0 0.401 
PANSS-Depression 12.4 ± 4.1 14.1±4.9 11.8±3.5 0.003 
24 
 
PANSS-Excitation 10.7 ± 4.4 10.8±4.1 10.7±4.5 0.810 
Suicidal ideation (item 8 CDSS) 0.4±0.8 1.0±1.1 0.3±.6 <0.001 
DAI scale 15.8±2.3 16.0±2.2 15.7±2.4 0.479 
UKU modified scale
 
5.8±4.5 5.9±3.5 5.8±4.8 0.127 
SCIP: Screen for Cognitive Impairment in Psychiatry; PANSS: Positive and Negative Syndrome Scale 
for Schizophrenia; CDSS:  Calgary Depression Scale for Schizophrenia; DAI: Drug Attitude inventory; 
MF: Markova & Berrios Insight scale; UKU: Udvalg for Kliniske Undersøgelser side effect rating scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Bivariate analyses: Relationships between nominal demographic and 
clinical variables, including clinical insight, and suicidality 
 Suicidality 
(item 8 CDSS) 
p-value 
Gender  Females 0.5 ± 0.9   
0.07 
Males 0.4 ± 0.8 
Marital status  Married 0.3 ± 0.7  
0.04 
Unmarried 0.5 ± 0.8 
Family psychiatric history  Present 0.4 ± 0.8  0.94 
25 
 
Absent 0.4 ± 0.8 
Living status  Alone 0.4 ± 0.9  
0.89 
Not alone 0.4 ± 0.8 
Education level  Low 0.3 ± 0.7  
0.19 
High 0.5 ± 0.8 
Employment status  Unemployed 0.5 ± 0.8  
<0.001 
employed 0.2 ± 0.4 
Illness duration <1 year  Present 0.3 ± 0.7  
0.26 
Absent 0.5 ± 0.8 
Diagnosis of schizophrenia  Present 0.4 ± 0.8  
0.91 
Absent 0.4 ± 0.8 
Previous suicidal behaviour  Present 1.0 ± 1.1   
<0.001 
Absent 0.3 ± 0.6 
Alcohol consumption  Present 0.6 ± 0.9   
0.10 
Absent 0.4 ± 0.8 
Drugs consumption Present 0.5 ± 0.9  0.78 
Absent 0.4 ± 0.8 
On Depot antipsychotic  Present 0.4 ± 0.8   
0.58 
Absent 0.5 ± 0.9 
On clozapine  Present 0.4 ± 0.8  
0.47 
Absent 0.5 ± 0.8 
On antidepressant (yes/no) Present 0.9 ± 1.2   
<0.001 
Absent 0.3 ± 0.7 
On mood stabilizer  Present 0.4 ± 1.0   0.58 
Absent 0.4 ± 0.8 
Insight mental illness  Good 0.7 ± 1.1  <0.001 
Poor 0.4 ± 0.7 
Insight need for treatment Good 0.4 ± 0.8  0.74 
Poor 0.4 ± 0.8 
Insight social consequences  Good            0.6 ± 0.9   0.04 
Poor 0.4 ± 0.8 
Cognitive impairment  Present 0.5 ± 0.9  0.38 
26 
 
           Absent 0.4 ± 0.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3, Bivariate correlations of suicidality (CDSS item 8) with demographic and 
clinical variables, including subjective insight  
 r p-value 
Age at assessment (years) 0.02 0.84 
Hospital admissions lifetime 0.03 0.77 
Total Markova & Berrios Insight scale 0.35 <0.001 
MF1 (awareness of disturbed thinking and loss 
of control over the situation) 
0.36 <0.001 
27 
 
MF2 (acknowledgment things outside as well as 
within the individual feel different) 
0.04 0.67 
MF3 (vague feeling that something is wrong) 0.20 0.02 
MF4 (attributing perceived changes to physical 
problems) 
0.09 0.28 
Total PANSS scale 0.27 <0.001 
PANSS-Positive 0.10 0.24 
PANSS-Negative 0.31 <0.001 
PANSS-Disorganized 0.11 0.11 
PANSS-Depression 0.45 <0.001 
PANSS- Excitation -0.02 0.84 
DAI scale 0.08 0.38 
UKU scale 0.10 0.24 
PANSS: Positive and Negative Syndrome Scale for Schizophrenia; CDSS subtotal:  Summary Calgary 
Depression Scale for Schizophrenia without item 8; DAI: Drug Attitude inventory;            
MF: Markova & Berrios Insight scale; UKU: Udvalg for Kliniske Undersøgelser side effect rating scale 
28 
 
 
Table 4. Final multivariable linear regression model on suicidality, including 
significant and non-significant predictors of suicidality.   
PANSS: Positive and  Negative Syndrome Scale for Schizophrenia 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predictors R²change B SE p 
Marital status (unmarried) 0.003 -0.011 0.051 0.833 
Employment status (unemployed) 0.015 -0.177 0.218 0.418 
Previous suicidal behaviour 0.133 0.368 0.153 0.018 
Negative symptoms ( PANSS factor) 0.056 0.011 0.007 0.160 
Depression (PANSS factor) 0.096 0.068 0.019 <0.001 
Insight mental illness  0.032 -0.274 0.163 0.095 
Insight social consequences  0.003 -0.092 0.164 0.577 
Total Markova & Berrios Insight scale 0.007 0.015 0.013 0.257 
 34.5%    
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Highlights 
- Suicidal behaviour in patients with psychosis represents a focus of concern. 
- Suicide risk factors differ from the general population. 
- There is no evidence to support a direct link of insight dimensions  with suicidality.  
- Depression and suicidal history predict further suicide attempts. 
 
 
 
